Please login to the form below

Not currently logged in
Email:
Password:

Castleman's disease

This page shows the latest Castleman's disease news and features for those working in and with pharma, biotech and healthcare.

Roche snags pair of FDA breakthrough designations

Roche snags pair of FDA breakthrough designations

drug. In J-ALEX - conducted by Roche's Japanese subsidiary Chugai - Alecensa reduced the risk of disease-worsening or death by 66% compared to Xalkori. ... First launched in Japan for 2005 for Castleman's disease - and subsequently getting the green

Latest news

  • Roche wins early use RA approval for RoActemra in Europe Roche wins early use RA approval for RoActemra in Europe

    Roche wins early use RA approval for RoActemra in Europe. Adds to existing indications in arthritis and Castleman’ s disease. ... The study showed patients on the combination experienced a significantly greater improvement in disease activity (DAS28

  • EC approves Janssen rare blood disorder drug EC approves Janssen rare blood disorder drug

    EC approves Janssen rare blood disorder drug. Sylvant available to treat multicentric Castleman's disease. ... Janssen's Sylvant this week became the first drug approved in Europe to treat the rare blood disorder multicentric Castleman's disease (MCD).

  • FDA approves Janssen drug for rare Castleman’s disease FDA approves Janssen drug for rare Castlemans disease

    FDA approves Janssen drug for rare Castleman’ s disease. Sylvant approved to treat lymphoma-like condition. ... It is also designated an orphan drug due to the rarity of multicentric Castleman's disease.

  • EMA backs Janssen rare disease drug for approval EMA backs Janssen rare disease drug for approval

    EMA backs Janssen rare disease drug for approval. Castleman's disease treatment Sylvant wins CHMP recommendation. ... J&J subsidiary Janssen-Cilag's Castleman's disease treatment Sylvant (situximab) has been recommended for approval in Europe.

  • J&J positive about pipeline

    The stable of products that are nearing readiness to be filed with regulators in the US and EU includes bapineuzumab IV for Alzheimer's disease, which the company acquired from Elan ... Also on the list are fulranumab for osteoarthritis pain; siltuximab

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics